Marker Therapeutics, Inc.
Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology company developing T cell therapies for blood cancers and solid tumors. Its Multi Antigen Recognizing (MAR)-T platform expands naturally occurring, tumor-specific T cells from a patient’s or donor’s blood without genetic modification; the… From the company’s description.
In fiscal 2025, Marker Therapeutics, Inc. reported revenue of $3.55M, down 46.2% from fiscal 2024, and a net loss of $12.16M. Its operating margin was −363.5%, and operations used $12.01M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Marker Therapeutics, Inc. does
In the company’s own words
Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology company developing T cell therapies for blood cancers and solid tumors. Its Multi Antigen Recognizing (MAR)-T platform expands naturally occurring, tumor-specific T cells from a patient’s or donor’s blood without genetic modification; the cells are designed to recognize multiple tumor antigens. The company’s lead candidate, MT-601, is being studied for relapsed lymphoma and pancreatic cancer, while its off-the-shelf MT-401-OTS program is being studied for acute myeloid leukemia and myelodysplastic syndromes. The company’s clinical development includes the Phase 1 APOLLO study of MT-601 in lymphoma and the Phase 1 RAPID study of MT-401-OTS. Marker licensed the underlying MAR-T technology from Baylor College of Medicine in 2018 and continues to collaborate with the institution on research and manufacturing. Its clinical history includes studies involving more than 150 patients conducted by Baylor.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- HOUSTON, TX
- Fiscal year end
- December
- CIK
- 1094038
- SIC
- 2834
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Marker Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Marker Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Marker Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Marker Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Marker Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”